# Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients

> **NCT02386007** · PHASE2 · UNKNOWN · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Acute and Chronic Gastric Inflammation Patients

## Interventions

- **DRUG:** DW-3101_150mg
- **DRUG:** DW-3101_300mg
- **DRUG:** DW-3101_600mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02386007
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** 2017-07
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386007, "Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02386007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*